NEUROPILOT VR

Neuropilot VR: Transforming Mental Wellness with Cutting-Edge Virtual Reality Solutions

Neuropilot VR is a pioneering mental health technology company dedicated to revolutionizing anxiety treatment through the integration of advanced neuroscience, innovative psychology, and immersive virtual reality (VR) therapy. At the heart of Neuropilot’s solutions is The Desire Therapy (TDT), an evidence-based methodology developed by co-founder and renowned psychotherapist Maia Tskitishvili. Leveraging TDT, Neuropilot VR offers personalized, non-invasive, and highly effective mental health solutions for individuals and organizations worldwide.
 

The Problem We Solve

Anxiety disorders are the most common mental health conditions globally, affecting over 301 million people, yet only 1 in 4 individuals receives effective care. Traditional therapies face significant barriers, including high costs, lack of accessibility, long durations, and a risk of retraumatization. In addition, these methods often struggle to adapt to the fast-paced demands of modern life, leaving millions underserved.

Neuropilot VR addresses these challenges by combining the therapeutic power of TDT with immersive VR technology, enabling individuals to access precise, real-time anxiety management tools in as little as five minutes per session.

Our Innovative Solution: Neuropilot VR and TDT

Neuropilot VR: The Desire Therapy (NVRTDT) is an advanced VR-based therapeutic platform designed to enhance mental well-being and cognitive performance. Using qEEG data and state-of-the-art mental imagery interventions, Neuropilot VR offers:

• Precision: Targeting specific brain regions associated with anxiety, such as the amygdala, pineal gland, and cerebellum.
• Efficiency: Delivering measurable results in short, 5-minute VR sessions.
• Safety: Avoiding exposure to past traumas, focusing instead on rewiring neural pathways to reduce anxiety symptoms naturally.
• Accessibility: Providing solutions that require minimal supervision, making them ideal for corporate wellness, clinical therapy, and individual use.

Neuropilot VR is grounded in over six years of rigorous research, 2,200 therapy sessions, and successful trials across Georgia. Research results were submitted at AAPB 53rd Annual Scientific Meeting, 2023 Florida, USA. Empirical studies confirm its efficacy in reducing beta wave activity, improving frontal alpha asymmetry, and enhancing relaxation responses in high-stress environments.

Market Opportunity

The global market for anxiety disorder treatment is projected to reach $16.1 billion by 2032, while the wellness industry continues to grow at an 8.6% CAGR. Neuropilot VR is uniquely positioned to capitalize on this opportunity by addressing unmet needs in high-pressure environments such as professional sports, corporate leadership, and healthcare.

Neuropilot’s B2B SaaS model provides scalable solutions for clinics, sports organizations, and corporations, offering cost-effective subscription packages tailored to their needs.

Our Track Record

Neuropilot VR has already achieved significant milestones, including:

• Partnerships with global organizations such as Toyota Caucasus, Georgian Rugby Union, and the Japan Basketball Association.
• Recognition through awards and competitions, including Expertise France Prize (VivaTech 2024), Georgian Innovation Day (Tokyo, 2023) and winning 2 pitch competitions in Japan in 2024.
• Validation through studies with athletes, corporate executives, and healthcare professionals, showcasing measurable reductions in anxiety and improved performance.

Why Invest in Neuropilot VR?

Neuropilot VR represents a rare convergence of cutting-edge technology, evidence-based psychology, and an unmet market need. By addressing a $16 billion market opportunity with a scalable, validated solution, Neuropilot is poised for rapid growth and global impact.

• Breakthrough Innovation: The Desire Therapy (TDT) is an entirely novel approach to anxiety treatment, with proven efficacy and immediate results.
• Global Expansion Potential: Initial focus on Europe, North America, and Asia, with plans for wider adoption in mental health care and corporate wellness.
• Scalability: Our SaaS model ensures sustainable revenue generation and ease of integration across diverse sectors.
• Social Impact: By democratizing access to mental health care, Neuropilot VR is reducing stigma, enhancing productivity, and improving quality of life.

Vision and Ambitions

Our goal is to set a new global standard in mental wellness by expanding Neuropilot VR into clinics, corporate wellness programs, and individual markets. We aim to secure FDA and CE certifications to position NVRTDT as a trusted medical device, revolutionizing anxiety treatment and mental health care worldwide.

Investing in Neuropilot VR means supporting a future where mental health solutions are accessible, effective, and transformative. Together, we can unlock the potential of immersive technology to create a healthier, more resilient world.